DVAX - DYNAVAX TECHNOLOGIES CORP
IEX Last Trade
12.91
-0.140 -1.084%
Share volume: 12,617
Last Updated: Fri 27 Dec 2024 05:29:53 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$13.05
-0.14
-1.07%
Fundamental analysis
13%
Profitability
7%
Dept financing
25%
Liquidity
75%
Performance
0%
Performance
5 Days
0.08%
1 Month
1.42%
3 Months
18.34%
6 Months
16.52%
1 Year
-8.48%
2 Year
19.00%
Key data
Stock price
$12.91
DAY RANGE
$12.94 - $13.08
52 WEEK RANGE
$10.20 - $15.01
52 WEEK CHANGE
-$9.77
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Ryan Spencer
Region: US
Website: dynavax.com
Employees: 350
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: dynavax.com
Employees: 350
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in the vaccine. The company was formerly known as Double Helix Corporation.
Recent news